Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to clostridium difficile infection

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 5, 2014, Pages 2767-2774

  Bassis, Christine M ^a   Theriot, Casey M ^a   Young, Vincent B ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOPERAZONE; RNA 16S; SODIUM CHLORIDE; TIGECYCLINE; MINOCYCLINE;

AMPLICON; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL SPORE; BACTERIAL STRAIN; BACTEROIDACEAE; BACTEROIDALES; BACTEROIDETES; CECUM; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY STRUCTURE; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENTEROBACTERIACEAE; FECES MICROFLORA; FEMALE; FIRMICUTES; FOLLOW UP; GENE SEQUENCE; HISTOPATHOLOGY; INTESTINE FLORA; MALE; MICROBIAL COMMUNITY; MICROBIAL DIVERSITY; MOUSE; NONHUMAN; PORPHYROMONADACEAE; PRIORITY JOURNAL; PROTEOBACTERIA; RIKENELLACEAE; RNA 16S GENE; SEQUENCE ANALYSIS; VERRUCOMICROBIUM; WILD TYPE; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CLOSTRIDIUM INFECTIONS; DRUG EFFECTS; GASTROINTESTINAL TRACT; MICROBIOLOGY; MICROFLORA; PATHOGENICITY; PEPTOCLOSTRIDIUM DIFFICILE;

ANIMALS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FEMALE; GASTROINTESTINAL TRACT; MALE; MICE; MICE, INBRED C57BL; MICROBIOTA; MINOCYCLINE;

EID: 84898662818     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02262-13     Document Type: Article

References (41)

1. McDonald LC, Lessa F, Sievert D, Wise M, Herrera R, Gould C, Malpiedi P, Dudeck M, Srinivasan A, Fridkin S, Cardo D. 2012. Vital signs: preventing Clostridium difficile infections. MMWR Morb. Mortal. Wkly. Rep. 61:157-162.
2. Freeman J, Wilcox MH. 1999. Antibiotics and Clostridium difficile. Microbes Infect. 1:377-384. http://dx.doi.org/10.1016/S1286-4579(99)80054-9.
3. Pépin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, Leblanc M, Rivard G, Bettez M, Primeau V, Nguyen M, Jacob CE, Lanthier L. 2005. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-Associated diarrhea: a cohort study during an epidemic in Quebec. Clin. Infect. Dis. 41:1254-1260. http://dx.doi.org/10.1086/496986.
4. Baxter R, Ray GT, Fireman BH. 2008. Case-control study of antibiotic use and subsequent Clostridium difficile-Associated diarrhea in hospitalized patients. Infect. Control Hosp. Epidemiol. 29:44-50. http://dx.doi.org/10.1086/ 524320.
5. Gifford AH, Kirkland KB. 2006. Risk factors for Clostridium difficileassociated diarrhea on an adult hematology-oncology ward. Eur. J. Clin. Microbiol. Infect. Dis. 25:751-755. http://dx.doi.org/10.1007/s10096-006-0220- 1.
6. Reeves AE, Theriot CM, Bergin IL, Huffnagle GB, Schloss PD, Young VB. 2011. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile infection. Gut Microbes 2:145-158. http://dx.doi.org/10.4161/gmic.2.3.16333.
7. Buffie CG, Jarchum I, Equinda M, Lipuma L, Gobourne A, Viale A, Ubeda C, Xavier J, Pamer EG. 2012. Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect. Immun. 80: 62-73. http://dx.doi.org/10.1128/IAI.05496-11.
8. Chang JY, Antonopoulos DA, Kalra A, Tonelli A, Khalife WT, Schmidt TM, Young VB. 2008. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-Associated diarrhea. J. Infect. Dis. 197:435-438. http://dx.doi.org/10.1086/525047.
9. Wilcox MH. 2007. Evidence for low risk of Clostridium difficile infection associated with tigecycline. Clin. Microbiol. Infect. 13:949-952. http://dx.doi.org/10.1111/j.1469-0691.2007.01792.x.
10. Wilcox MH. 2005. Efficacy of tigecycline in complicated skin and skin structure infections and complicated intra-Abdominal infections. J. Chemother.(Suppl 1):23-29. http://dx.doi.org/10.1179/joc.2005.17.Supplement-1. 23.
11. Townsend ML, Pound MW, Drew RH. 2011. Potential role of tigecycline in the treatment of community-Acquired bacterial pneumonia. Infect. Drug Resist. 4:77-86. http://dx.doi.org/10.2147/IDR.S6030.
12. Petersen PJ, Bradford PA, Weiss WJ, Murphy TM, Sum PE, Projan SJ. 2002. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant Gram-positive pathogens. Antimicrob. Agents Chemother. 46:2595-2601. http://dx.doi.org/10.1128/AAC.46.8.2595-2601. 2002.
13. Lu CL, Liu CY, Liao CH, Huang YT, Wang HP, Hsueh PR. 2010. Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole. Int. J. Antimicrob. Agents. 35:311-312. http://dx.doi.org/ 10.1016/j.ijantimicag.2009.11.008.
14. Herpers BL, Vlaminckx B, Burkhardt O, Blom H, Biemond-Moeniralam HS, Hornef M, Welte T, Kuijper EJ. 2009. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin. Infect. Dis. 48:1732-1735. http://dx.doi.org/10.1086/599224.
15. Hawser SP. 2010. Activity of tigecycline against recent European clinical isolates of Clostridium difficile. Int. J. Antimicrob. Agents. 35:97-98. http://dx.doi.org/10.1016/j.ijantimicag.2009.09.009.
16. Tang HJ, Ko WC, Chen CC, Chen PL, Toh HS, Weng TC, Yu WL, Chiang SR, Chuang YC. 2011. In vitro and in vivo intracellular killing effects of tigecycline against clinical nontyphoid Salmonella isolates using ceftriaxone as a comparator. Antimicrob. Agents Chemother. 55:2755-2759. http://dx.doi.org/10. 1128/AAC.01807-10.
17. Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN. 2007. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob. Agents Chemother. 51:2716-2719. http://dx.doi.org/10.1128/AAC.01623-06.
18. Jump RL, Li Y, Pultz MJ, Kypriotakis G, Donskey CJ. 2011. Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production. Antimicrob. Agents Chemother. 55:546-549. http://dx.doi.org/10.1128/AAC.00839-10.
19. Nord CE, Sillerström E, Wahlund E. 2006. Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob. Agents Chemother. 50:3375-3380. http://dx.doi.org/10.1128/AAC.00373-06.
20. Theriot CM, Koumpouras CC, Carlson PE, Bergin II, Aronoff DM, Young VB. 2011. Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains. Gut Microbes 2:326-334. http://dx.doi.org/10.4161/gmic.19142.
21. Perez J, Springthorpe VS, Sattar SA. 2011. Clospore: a liquid medium for producing high titers of semi-purified spores of Clostridium difficile. J. AOAC Int. 94:618-626.
22. Schloss PD, Gevers D, Westcott SL. 2011. Reducing the effects of PCR amplification and sequencing artifacts on 16S rRNA-based studies. PLoS One 6:e27310. http://dx.doi.org/10.1371/journal.pone.0027310.
23. Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, Lesniewski RA, Oakley BB, Parks DH, Robinson CJ, Sahl JW, Stres B, Thallinger GG, Van Horn DJ, Weber CF. 2009. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl. Environ. Microbiol. 75:7537-7541. http://dx.doi.org/10.1128/AEM.01541-09.
24. Quince C, Lanzén A, Curtis TP, Davenport RJ, Hall N, Head IM, Read LF, Sloan WT. 2009. Accurate determination of microbial diversity from 454 pyrosequencing data. Nat. Methods 6:639-641. http://dx.doi.org/10.1038/nmeth. 1361.
25. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, Peplies J, Glöckner FO. 2013. The SILVA ribosomal RNA gene database project: improved data processing and Web-based tools. Nucleic Acids Res. 41: D590-D596. http://dx.doi.org/10.1093/nar/gks1219.
26. Schloss PD. 2009. A high-throughput DNA sequence aligner for microbial ecology studies. PLoS One 4:e8230. http://dx.doi.org/10.1371/journal.pone. 0008230.
27. Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R. 2011. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics 27: 2194-2200. http://dx.doi.org/10.1093/bioinformatics/btr381.
28. Cole JR, Chai B, Farris RJ, Wang Q, Kulam SA, McGarrell DM, Garrity GM, Tiedje JM. 2005. The Ribosomal Database Project (RDP-II): sequences and tools for high-throughput rRNA analysis. Nucleic Acids Res. 33:D294-D296. http://dx.doi.org/10.1093/nar/gki038.
29. Wang Q, Garrity GM, Tiedje JM, Cole Jr. 2007. Naïve Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl. Environ. Microbiol. 73:5261-5267. http://dx.doi.org/10.1128/AEM. 00062-07.
30. Yue JC, Clayton MK. 2005. A similarity measure based on species proportions. Commun. Statist.-Theor. Method. 34:2123-2131. http://dx.doi.org/10. 1080/STA-200066418.
31. Theriot CM, Koenigsknecht MJ, Carlson PE, Jr, Hatton GE, Nelson AM, Li B, Huffnagle GB, Li JZ, Young VB. 2014. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat. Commun. 5:3114. http://dx.doi.org/10.1038/ncomms4114.
32. Antonopoulos DA, Huse SM, Morrison HG, Schmidt TM, Sogin ML, Young VB. 2009. Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation. Infect. Immun. 77: 2367-2375. http://dx.doi.org/10.1128/IAI.01520-08.
33. Lawley TD, Clare S, Walker AW, Stares MD, Connor TR, Raisen C, Goulding D, Rad R, Schreiber F, Brandt C, Deakin LJ, Pickard DJ, Duncan SH, Flint HJ, Clark TG, Parkhill J, Dougan G. 2012. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog. 8:e1002995. http://dx.doi.org/10.1371/ journal.ppat.1002995.
34. Skraban J, Dzeroski S, Zenko B, Mongus D, Gangl S, Rupnik M. 2013. Gut microbiota patterns associated with colonization of different Clostridium difficile ribotypes. PLoS One 8:e58005. http://dx.doi.org/10.1371/journal.pone. 0058005.
35. Manges AR, Labbe A, Loo VG, Atherton JK, Behr MA, Masson L, Tellis PA, Brousseau R. 2010. Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridum difficileassociated disease. J. Infect. Dis. 202:1877-1884. http://dx.doi.org/10.1086/657319.
36. Rea MC, O'Sullivan O, O'Toole PW, Stanton C, Ross RP, Hill C. 2012. Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J. Clin. Microbiol. 50:867-875. http://dx.doi.org/10. 1128/JCM.05176-11.
37. Hopkins MJ, Macfarlane GT. 2002. Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. J. Med. Microbiol. 51:448-454.
38. Hamilton MJ, Weingarden AR, Unno T, Khoruts A, Sadowsky MJ. 2013. High-throughputDNAsequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes 4:125-135. http://dx.doi.org/10.4161/gmic.23571.
39. Theriot CM, Young VB. 11 December 2013. Microbial and metabolic interactions between the gastrointestinal tract and infection. Gut Microbes. http://dx.doi.org/10.4161/gmic.27131.
40. Robinson CJ, Young VB. 2010. Antibiotic administration alters the community structure of the gastrointestinal micobiota. Gut Microbes 1:279-284. http://dx.doi.org/10.4161/gmic.1.4.12614.
41. Baines SD, Saxton K, Freeman J, Wilcox MH. 2006. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. J. Antimicrob. Chemother. 58:1062-1065. http://dx.doi.org/10.1093/jac/dkl364.